Skip to main content

Catalyst Calendar

Tue, Oct 6, 2026

1 updates

7:30 AM

SCYNEXIS Announces Phase 1 Study Results for SCY-770, a Novel, Highly Selective, Oral Direct AMPK Activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

Trial Results • Phase 1oral presentation Tue, Oct 6, 2026, 7:30 AM EDTscynexis.com

Mon, Sep 28, 2026

1 updates

7:30 AM

SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247

scynexis.com

Tue, Sep 22, 2026

1 updates

8:00 AM

SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors

scynexis.com

Tue, Sep 15, 2026

1 updates

8:00 AM

SCYNEXIS Appoints Todd Minga, M.D., as Senior Vice President, Research & Development

scynexis.com

Thu, Sep 10, 2026

1 updates

8:00 AM

SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer

scynexis.com

Tue, Sep 1, 2026

1 updates

8:30 AM

SCYNEXIS to Participate in Upcoming Investor Conferences

scynexis.com

Tue, Aug 25, 2026

1 updates

7:06 PM

SCYNEXIS Announces Inducement Award Under Nasdaq Listing Rule 5635(c)(4)

scynexis.com

Mon, Aug 10, 2026

1 updates

4:30 PM

SCYNEXIS Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Trial Start • Phase 1Trial initiation Tue, Jun 30, 2026, 4:30 PM EDTscynexis.com